Harm reduction - From a conceptual framework to practical experience: The example of germany

Substance Use and Misuse

Volumn 47, Issue 8-9, 2012, Pages 910-922

  Michels, Ingo Ilja ^a   Stöver, Heino ^b  

^a Office of the Federal Drug Commissioner   (Germany)

^b FRANKFURT UNIVERSITY OF APPLIED SCIENCES   (Germany)

Author keywords

dependence; harm reduction measures; needle syringe exchange programs; opiate substitution treatment; risk competence; supervised injecting facilities (sif)

Indexed keywords

ARTICLE; EVIDENCE BASED PRACTICE; GERMANY; HARM REDUCTION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTEGRATED HEALTH CARE SYSTEM; PREVENTIVE HEALTH SERVICE; PRISON; SANITATION; SOCIAL SUPPORT; SUBSTANCE ABUSE;

DELIVERY OF HEALTH CARE, INTEGRATED; EVIDENCE-BASED PRACTICE; GERMANY; HARM REDUCTION; HIV INFECTIONS; HUMANS; NEEDLE-EXCHANGE PROGRAMS; PRISONS; PUBLIC FACILITIES; SOCIAL SUPPORT; SUBSTANCE ABUSE, INTRAVENOUS;

EID: 84862529486     PISSN: 10826084     EISSN: 15322491     Source Type: Journal    
DOI: 10.3109/10826084.2012.663281     Document Type: Article

References (61)

1. American Psychiatric Association. (1994). Diagnostic and statistical manual of mental disorders (DSM-IV) (4th ed.).Washington, DC: Author.
2. Backmund, M. (2007). Suchttherapie. Grundlagen, Klinik, Standards (12th ed.) [Addiction therapy. Basic knowledge, clinic, standards]. Munich: Ecomed.
3. B̈ollinger, L., & Sẗover, H. (2002). Drogenrecht, Drogenpraxis, Drogenpolitik [Drug laws, drug reality and drug policy]. Frankfurt am Main: Fachhochschulverlag.
4. Bossong, H. (1991). Kritische Bestandsaufnahme zur aktuellen Drogenpolitik. Werkstattgespr̈ache Drogenpolitik [Critical review on current drug policy. Workshop talk on drug policy]. Bonn: Juso-Bundesvorstand.
5. Bschor, F. (1983). Mortality of drug dependent patients in international comparison. Lebensversicherungs Medizin, 35, 74-80.
6. B̈uhringer, G. (2006). Allocating treatment options to patients profiles: clinical art or science? Addiction, 101, 646-652.
7. Bundes̈arztekammer. (2010, March 19). Richtlinien der Bundes ̈arztekammer zur Durchf̈uhrung der substitutionsgesẗutzten Behandlung Opiatabḧangiger [Guidelines of the Federal Chamber of Medical Doctors for implementation of substitution-assisted treatment of opiate dependents] (Vol. 107, pp. A511'B516). Berlin: Deutsches Ärzteblatt.
8. Buscema, M. (1998). Artificial neural networks. Substance Use & Misuse, 33, 1-3.
9. Commission of the European Communities. (2007, April 18). Report from the Commission to the European Parliament and the Council on the implementation of the Council Recommendation of 18 June 2003 on the prevention and reduction of health-related harm associated with drug dependence [Doc. No. COM(2007) 199 final] Brussels.
10. Degkwitz, P., Chorzelski, G., & Krausz, M. (1993, July 1-2). Five years of methadone prescription in Germany. In M. Reisinger (Ed.), Aids and drug addiction in the European community (pp. 81-89), Proceedings of a Seminar on AIDS and Drug Addiction in the Twelve European CommunitiesMember States. Brussels: European Monitoring Centre forDrugs andDrugAddiction (EMCDDA).
11. Dolan, K., Kimber, J., Fry, C., Fitzgerald, J., Mcdonald, D., & Trautmann, F. (2000). Drug consumption facilities in Europe and the establishment of supervised injecting centers in Australia. Drug and Alcohol Review, 19, 337-346.
12. Gerlach, R. (2002). Drug substitution treatment in Germany: A critical overview of its history, legislation and current practice. Journal on Drug Issues, 2, 503-522.
13. G̈olz, J. (1998). Moderne Suchtmedizin [Modern addiction medicine]; Stuttgart/New York: Thieme.
14. Haasen, C. (2011). The German model project for heroin assisted treatment of opioid dependent patients - a multi centre, randomized, controlled trial. Retrieved March 31, 2011, from http://www.heroinstudie.de/Summ German H-Study.pdf
15. Haasen, C., Verthein, U., Degkwitz, P., Berger, J., Krausz, M., & Naber, D. (2006). Heroin-Assisted treatment for opioid dependence-a randomised, controlled clinical trial (Report to the Federal Ministry of Health). Berlin: Federal Ministry of Health.
16. Haasen, C., Verthein, U., Degkwitz, P., Berger, J., Krausz, M., & Naber, D. (2007). Heroin-assisted treatment for opioid dependence: randomised controlled trial. British Journal of Psychiatry, 191, 55-62. (Pubitemid 47035182)
17. Hedrich, D. (2004). European report on drug consumption rooms. Lisbon: European Monitoring Center of Drugs and Drug Addiction.
18. Hedrich, D., Kerr Th., & Dubois-Arber, F. (2010). Drug consumption facilities in Europe and beyond. In T. Rhodes & D. Hedrich (Eds.), Harm reduction: evidence, impacts and challenges (pp. 305-332). Lisbon: EMCDDA Monographs.
19. Kastelic, A., Pont, J., & Sẗover, H. (2008). Opioid substitution treatment in custodial settings: A practical guide. Oldenburg: WHO/UNODC.
20. Kimber, J., Dolan, K., van Beek, I., Hedrich, D., & Zurhold, H. (2003). Drug consumption facilities: An update since 2000. Drug and Alcohol Review, 22, 227-233. (Pubitemid 36814874)
21. Kimber, J., Dolan, K., & Wodak, A. (2002). International survey of supervised injecting centres (1999-2000). Sydney: National Drug and Alcohol Research Centre.
22. Kleiber, D.,&Pant, A. (1996). HIV-needle-sharing-sex. Bonn: Federal Ministry of Health.
23. K̈orner, H. H. (1993, May). Strafrechtliches Gutachten zur Zul̈assigkeit von Gesundheitsr̈aumen f̈ur den hygienischen und stressfreien Konsum von Opiatabḧangigen [Penal expertise on legitimacy of healthy rooms for hygenic and stress-free consumption of opiate dependents]. Wiesbaden: Zentralstelle zur Bek̈ampfung der Beẗ aubungsmittelkriminliẗat.
24. Krach, C., Lotze, J., Peschke, H., Peter, U., Rabe, M. L., Scḧonhofer, P. et al. (1978). Ambulantes Therapieprogramm mit Methadon [Out-patient therapy program with Methadone]. Niedersächsisches Ärzteblatt, 51, 289-293.
25. Kraus L.,Pabst A.,2010 Epidemiologischer Suchtsurvey 2009 [Epidemiological survey on substance abuse 56 3 309-384
26. Krausz, M., Verthein, U., Degkwitz, P., Haasen, C., & Raschke, P. (1998). Maintenance treatment of opiate addicts in Germany with medications containing codeine-results of a follow-up study. Addiction, 93, 1161-1167. (Pubitemid 28370589)
27. Michels, I. I. (1993, July 1-2). Critical analysis of the drug treatment policy in Germany. In M. Reisinger (Ed.), Aids and drug addiction in the European community. Proceedings of a Seminar on AIDS and Drug Addiction in the Twelve European Communities Member States, Brussels. Lisbon: European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)
28. Michels, I. I. (2002). Heroin based treatment. Journal on Drug Issues, 2, 523-542.
29. Michels, I. I. (2005). Substitutionsbehandlungen in Deutschland -vom Tal der Tr̈anen in die M̈uhen der Ebene [Substitution treatment in Germany - from the valley of tears to the hardship of the plain]. In R. Gerlach & H. Sẗover (Eds.), Vom Tabu zur Normaliẗat. 20 Jahre Substitution in Deutschland. Zwischenbilanz und Aufgaben f̈ur die Zukunft. Freiburg i.Br.: Lambertus.
30. Michels, I. I., Sander, G.,&Sẗover,H. (2009). Praxis, Probleme und Perspektiven der Substitutionsbehandlung Opioidabḧangiger in Deutschland [Practice, problems and perspectives of substitution treament for opioid dependents]. Bundesgesundheitsblatt-Gesundheitsforschung- Gesundheitsschutz, 52, 111-121.
31. Michels, I., Sẗover, H., & Gerlach, R. (2007). Substitution treatment for opioid dependents in Germany. International Journal of Harm Reduction, 4, 5.
32. Michels, I. I., Sẗover, H., & Schuller, K. (1990, April 9-12). The availability of sterile syringes in the Federal Republic of Germany. Paper presented on the 1st International Conference on the Reduction of Drug Related Harm, Liverpool, England.
33. Ministerium NRW (Ministerium f̈ur Arbeit, Gesundheit und Soziales des Landes Nordrhein-Westfalen) (Ed.). (1998). Medikamentengesẗutzte Rehabilitation i.v. Opiatabḧangiger-Katamnese [Medication-supported rehabilitation of i.v. drug addicts-follow-up]. D̈usseldorf: Author.
34. Newcombe, R. (1992). The reduction of drug related harm: A conceptual framework fort theory, practice and research. (pp. 1-14)In P. O'Hare, et al. (Eds.), The reduction of drug related harm. London and New York.
35. Newman, R. G. (1988). Is there a role for methadone in Germany? AIDS & Public Policy Journal, 3, 23-29.
36. Newman, R. G. (1995). Another wall that crumbled-methadone maintenance treatment in Germany. American Journal of Drug & Alcohol Abuse, 21, 27-35.
37. Pabst, A., Piontek, D., Kraus, L.,&M̈uller, S. (2010). Substanzkonsum und substanzbezogene Sẗorungen. Ergebnisse des Epidemiologischen Suchtsurveys 2009 [Substance use and substance use disorders. Results of the 2009 Epidemiological Survey of Substance Abuse]. Sucht, 56(5), 327-336.
38. Pfeiffer-Gerschel, T., & Simon, R. (2008). Cannabisbezogene Sẗorungen - NeueAnsätze in Pr̈avention und Behandlung. Sucht, 54(4), 229-233.
39. Pfeiffer-Gerschel, T., Kipke, I., Fl̈oter, S., Jakob, L., Hammes, D., & Raiser, P. (2011). Deutschland. Drogensituation 2010/2011. Neue Entwicklungen, Trends und Hintergrundinformationen zu Schwerpunktthemen [Germany. Drug situation 2010/2011. New developments, trends and in-depth information on selected issues]. Munich: Institute for Therapy Research.
40. Poschadel, S., Ḧoger, R., Schnitzler, J., & Schreckenberg, D.,(2003). Evaluation der Arbeit der Drogenkonsumr̈aume in der Bundesrepublik Deutschland [Evaluation of the work of Drug Consumption Rooms in Germany] (Vol. 149. Nomos). Baden-Baden: Schriftenreihe des Bundesministeriums f̈ur Gesundheit und Soziale Sicherheit.
41. Rhodes, T., & Hedrich, D. (2010). Harm reduction: evidence, impacts and challenges. Lisbon: EMCDDA Monographs.
42. Robert Koch Institut. (2010). Epidemiologisches Bulletin [Epidemiological bulletin], Nr. 46 from 22 November.
43. Schulte, B., Sẗover, H., Thane, K., Schreiter, C., Gansefort, D., & Reimer, J. (2009). Substitution treatment and HCV/HIV infection in German prisons. International Journal of Prisoner Health, 5(1), 39-44.
44. Stimson, G. (1989). Syringe-exchange programmes for injecting drug users. AIDS, 3, 253-260. (Pubitemid 19167465)
45. Sẗover,H. (1991). Der tolerierte intraven̈oseDrogengebrauch in den Angeboten der Drogen- und AIDS-Hilfe: Problembereiche und Perspektiven eines konsequenten Angebots der Ü berlebenshilfe und des Gesundheitsschutzes [Tolerated intravenous drug consumption in facilities of drug- and AIDS-services: problematic fields and perspectives of a consistent offer for survival assistance and health protection]. In Der tolerierte intraven̈ose Drogengebrauch in den Angeboten der Drogen- und AIDS-Hilfe [Tolerated intranevious drug consumption in facilities of drugandAIDS-services] (Vol. VI, pp. 9-22). Berlin: DeutscheAIDSHilfe, DAH-Forum.
46. Sẗover, H. (2002). Consumption rooms: A middle ground between health and public order concerns. In L. B̈ollinger, et al. (Eds.). Journal of Drug Issues, 32(2), 597-606.
47. Sẗover,H.,&Prinzleve,M. (Eds.). (2004). Kokain und Crack: Pharmakodynamiken, Hilfeangebote [Cocaine and crack: pharmacodynamics, aid services]. Freiburg: Lambertus.
48. Sẗover, H. (2011). Barriers to opioid substitution treatment access, entry and retention: A survey of opioid users, patients in treatment, and treating and non-treating physicians. European Addiction Research, 17, 44-54.
49. Sẗover, H., Casselman, J., & Hennebel, L. C. (2006). Substitution treatment in European prisons: A study of policies and practices of substitution treatment in prisons in 18 European countries. The International Journal of Prisoner Health, 2(1), 3-12. (Pubitemid 44106803)
50. Sẗover, H., & Michael, P. (Eds.). (2004). Kokain und Crack: Pharmakodynamiken, Hilfeangebote [Cocaine and Crack: Pharmokodynamics, support services]. Freiburg: Lambertus.
51. Sẗover, H., & Nelles, J. (2003). Ten years of experience with needle and syringe exchange programmes in European prisons. International Journal of Drug Policy, 14(5-6), 437-444. (Pubitemid 37412241)
52. Tossmann, P., Boldt, S., & Tensil, M. D. (2001). The use of drugs within the techno party scene in European metropolitan cities. European Addiction Research, 7, 2-23. (Pubitemid 32337195)
53. United Nations. (2002). Preventing the transmission of HIV among drug abusers: A position paper of the United Nations system. Vienna: Commission on Narcotic Drugs.
54. Van den Brink,W., & Haasen, C. (2006). Evidence based treatment of opiate dependent patients. Canadian Journal of Psychiatry, 10, 635-645.
55. Verthein, U., Bonorden-Kleij, K., Degkwitz, P., Dilg, C., K̈ohler, W.K., Passie, T., et al. (2008). Long-term effects of heroinassisted treatment in Germany. Addiction, 103, 960-966. (Pubitemid 351703473)
56. Verthein, U., Kalke, J.,&Raschke, P. (1998). Substitution treatment with methadone in Germany: politics, programmes and results. International Journal of Drug Policy, 9, 71-78. (Pubitemid 128413048)
57. Wittchen, H. U., Apelt, S. M., B̈uhringer, G., Gastpar, M., Backmund, M., G̈olz, J., et al. (2005). Buprenorphine and methadone in the treatment of opioid dependence: methods and design of the COBRA study. International Journal of Methods in Psychiatric Research, 14(1), 14-28. (Pubitemid 40613154)
58. Wittchen, H. U., Apelt, S. M., Soyke, Gastpar, M., Backmund, M., G̈olz, J., et al. (2008). Feasibility and outcome of substitution treatment of heroin-dependent patients in specialized substitution centers and primary care facilities in Germany: A naturalistic study in 2694 patients. Drug and Alcohol Dependence, 95(3), 245-257.
59. WHO (World Health Organization). (2009). Guidelines for psychosocially assisted pharmacological treatment of opioid dependence. Geneva: Author.
60. WHO/UNODC/UNAIDS. (2006). Substitution maintenance therapy in the management of opioid dependence and HIV/AIDS prevention: position paper, Geneva: Author.
61. Wood, E., Tyndall, M.W., Li, K., Lloyd-Smith, E., Small,W.,Montaner, J. S. G., et al. (2005). Do supervised injecting facilities attract higher risk injection drug users? American Journal of Preventive Medicine, 29(20), 126-130. (Pubitemid 40991183)